CJC-1295 and Ipamorelin: How They Work Together

CJC-1295 and Ipamorelin are among the most frequently paired peptides in growth-hormone research. This overview explains what each compound is, why they are studied together, and how their mechanisms differ — a look at the science, not a usage protocol.

Why CJC-1295 and Ipamorelin Are Studied Together

The two compounds act on two different points of the same axis. CJC-1295 is a GHRH analogue; Ipamorelin is a selective ghrelin-receptor secretagogue. Pairing them lets researchers examine how the GHRH and ghrelin signalling routes interact within the growth-hormone axis, which is why the combination appears so often in the literature.

CJC-1295: The GHRH Side

CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone, modified for greater stability than the native peptide. It is studied for its interaction with the GHRH receptor on the pituitary.

Ipamorelin: The Ghrelin Side

Ipamorelin is a selective growth-hormone secretagogue that acts at the ghrelin receptor, noted for comparatively little effect on cortisol and prolactin pathways relative to older secretagogues.

Forms, Purity and Handling

• Format: both supplied as lyophilised powder.

• Purity: greater than or equal to 99% by HPLC.

• COA: per batch.

• Storage: frozen for long-term stability; refrigerated once in solution.

Frequently Asked Questions

Why are CJC-1295 and Ipamorelin paired?

They act on different points of the growth-hormone axis — GHRH receptor and ghrelin receptor — so the combination is studied to examine how the two routes interact.

What is the difference between them?

CJC-1295 is a GHRH analogue; Ipamorelin is a selective ghrelin-receptor secretagogue.

What purity should they be?

Greater than or equal to 99% by HPLC with a per-batch COA for each.

These products are supplied strictly for laboratory and research use only. Not for human or animal consumption.